

PATENT

1645

Case Docket No. GNE.1618P2C31
Date: September 27, 2002

TECH CENTER 1600/2900


RECEIVED
OCT 07 2002

In re application of : Ashkenazi et al.
App. No. : 09/905,088
Filed : July 12, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND
NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Unknown
Art Unit : 1645

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, PO Box 2327, Arlington VA 22202, on

September 27, 2002

(Date)


Ginger R. Dreger, Reg. No. 33,055

United States Patent and Trademark Office
PO Box 2327
Arlington VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with two (2) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GNE.1618P2C31



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant : Ashkenazi et al.

) Group Art Unit 1645

App. No. : 09/905,088

)

Filed : July 12 2001

)

For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND
NUCLEIC ACIDS ENCODING
THE SAME

)

)

)

)

)

Examiner : Unknown

)

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

#13
P.Q.J
10/10/02SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
 PO Box 2327
 Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 2 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 27, 2002

By: Ginger R. Dreger
 Ginger R. Dreger
 Registration No. 33,055
 Attorney of Record
 2040 Main Street, 14th Floor
 Irvine, CA 92614
 (949) 760-0404

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GNE.1618P2C31	APPLICATION NO. 09/905,088
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Ashkenazi et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE July 12, 2001	GROUP 1645

RECEIVED

OCT 07 2001

TECH CENTER 1600/2900

EXAMINER INITIAL	TRADEMARK CITE IF	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1. <input checked="" type="checkbox"/>	Taguchi et al., "Molecular cloning of novel leucine-rich repeat proteins and their expression in the developing mouse nervous system," <i>Molecular Brain Research</i> , 35(1-2): 31-40 (1996).
	2. <input checked="" type="checkbox"/>	Almeida et al., "GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas," <i>Oncogene</i> , 16(23): 2997-3002 (1998)

W:\DOCS\BGY\BGY-2709.DOC
091902

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.